Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

The effect of the oral PKC β inhibitor ruboxistaurin on vision loss in two phase 3 studies.

Sheetz MJ, Aiello LP, Davis MD, Danis R, Bek T, Cunha-Vaz J, Shahri N, Berg PH; MBDL and MBCU Study Groups.

Invest Ophthalmol Vis Sci. 2013 Mar 11;54(3):1750-7. doi: 10.1167/iovs.12-11055.

PMID:
23404115
2.

Ruboxistaurin: LY 333531.

[No authors listed]

Drugs R D. 2007;8(3):193-9. Review.

PMID:
17472415
3.

Rubosixtaurin and other PKC inhibitors in diabetic retinopathy and macular edema. Review.

Gálvez MI.

Curr Diabetes Rev. 2009 Feb;5(1):14-7. Review.

PMID:
19199893
4.

Ruboxistaurin mesilate hydrate for diabetic retinopathy.

Schwartz SG, Flynn HW Jr, Aiello LP.

Drugs Today (Barc). 2009 Apr;45(4):269-74. doi: 10.1358/dot.2009.45.4.1354195. Review.

PMID:
19499092
5.

The Protein Kinase C Inhibitor: Ruboxistaurin.

Deissler HL, Lang GE.

Dev Ophthalmol. 2016;55:295-301. doi: 10.1159/000431204. Epub 2015 Oct 26. Review.

PMID:
26501476
6.

Ruboxistaurin.

Taulien CA, Joy SV.

Drugs Today (Barc). 2006 Sep;42(9):577-85. Review.

PMID:
17028667
7.

Pharmacotherapies for diabetic retinopathy: present and future.

Schwartz SG, Flynn HW Jr.

Exp Diabetes Res. 2007;2007:52487. Review.

8.

[Early treatment diabetic retinopathy study (ETDRS) visual acuity].

Told R, Baratsits M, Garhöfer G, Schmetterer L.

Ophthalmologe. 2013 Oct;110(10):960-5. doi: 10.1007/s00347-013-2813-2. Review. German.

PMID:
23779250
9.

Medical management of diabetic retinopathy.

Sjølie AK, Møller F.

Diabet Med. 2004 Jul;21(7):666-72. Review.

PMID:
15209756

Supplemental Content

Support Center